This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Tufts University, University of Kansas. Active years: 2008-2014.
Company Filing History:
4 out of 655 
1 out of 572 
Years Active: 2008-2014
Title: Innovations and Contributions of Inventor Jiazhou Qiu
Introduction
Jiazhou Qiu is a notable inventor based in Westborough, MA, with a significant contribution to the field of medical research. He holds a total of four patents, showcasing his innovative approach to addressing health-related challenges. His work primarily focuses on IgA1 deposition diseases, which are critical in understanding and treating various medical conditions.
Latest Patents
Among his latest patents, Jiazhou Qiu has developed polypeptide agents that are useful in the treatment of IgA1 deposition diseases. These polypeptide agents are designed to target and treat conditions associated with abnormal IgA1 levels. Additionally, he has disclosed methods for screening inhibitors of IgA1 proteases, which are essential for developing therapeutic agents. Another significant invention involves proteins that specifically bind to IgA1, modified to include O- or N-linked glycans. This invention encompasses methods for decreasing abnormally glycosylated IgA1 in individuals, providing a potential pathway for treating diseases characterized by IgA1 deposition.
Career Highlights
Jiazhou Qiu has worked with esteemed institutions such as Tufts Medical Center and the University of Kansas Medical Center Research Institute. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his research and innovation capabilities.
Collaborations
Some of his notable coworkers include Andrew G. Plaut and Todd Holyoak, who have contributed to his research endeavors. Their collaboration has played a vital role in advancing the understanding of IgA1-related diseases.
Conclusion
Jiazhou Qiu's innovative contributions to the field of medical research, particularly in the treatment of IgA1 deposition diseases, highlight his role as a significant inventor. His patents and collaborations reflect a commitment to improving health outcomes through scientific advancements.